doxorubicin administered by continuous infusion schedules was less cardiotoxic than when administered by bolus , as shown by a greater than 75 % decrease in the frequency of clinical congestive heart failure at cumulative dosages greater than or equal to 450 mg/m2 ( p = 0.004 ) .
C0013089
doxorubicin
C0018802
congestive heart failure